Quantum BioPharma Advances Dual Strategy for Neurological Health with Lucid-MS and unbuzzd

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing a two-pronged strategy to address neurological health, focusing on both a potential therapy for multiple sclerosis (MS) and a dietary supplement for alcohol metabolism. The company is developing Lucid-MS, an investigational therapy designed to target PAD2, an enzyme associated with myelin degradation, aiming to protect and potentially restore the myelin sheath. This approach differs from existing MS treatments that primarily modulate the immune system, offering a novel mechanism of action.

Quantum BioPharma has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 trial of Lucid-MS. The company is also supporting its development through an imaging collaboration with Massachusetts General Hospital, which is expected to provide valuable insights into the therapy's effects. This progress underscores Quantum BioPharma's commitment to advancing innovative therapies for challenging neurodegenerative diseases.

In parallel, Quantum BioPharma is addressing alcohol misuse disorders through its proprietary dietary supplement unbuzzd. The company cites results from a randomized, placebo-controlled clinical trial indicating that unbuzzd supports alcohol metabolism and reduces acute intoxication and hangover effects. This product represents a consumer-focused approach to a significant public health issue, with potential implications for reducing alcohol-related harm.

The company's dual strategy is part of a broader mission to build a portfolio of innovative assets for the treatment of neurodegenerative, metabolic, and alcohol misuse disorders. Quantum BioPharma retains ownership of 19.84% of UWI, the company that markets the OTC version of unbuzzd, and is entitled to royalty payments of 7% of sales until cumulative payments reach $250 million, after which the royalty drops to 3% in perpetuity. This arrangement provides Quantum BioPharma with a potential revenue stream while it continues to develop pharmaceutical-grade formulations for medical use.

Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models. By targeting PAD2, the therapy aims to address the underlying mechanism of MS rather than merely managing symptoms. This approach could offer a significant advancement in the treatment of MS, a condition that affects millions worldwide.

Quantum BioPharma's efforts are supported by its wholly owned subsidiary, Lucid Psycheceuticals Inc., which focuses on the research and development of Lucid-MS. The company's commitment to rigorous scientific research is evident in its collaboration with Massachusetts General Hospital and its pursuit of FDA approval for clinical trials.

The potential impact of these developments is substantial. For MS patients, Lucid-MS could provide a new therapeutic option that targets the root cause of the disease, potentially slowing or reversing disability progression. For individuals struggling with alcohol misuse, unbuzzd offers a non-prescription option to mitigate the effects of alcohol, which could support harm reduction strategies.

Investors and stakeholders are watching Quantum BioPharma's progress closely, as the company continues to advance its pipeline and explore new frontiers in neurological health. With its dual approach, Quantum BioPharma is positioning itself at the forefront of innovation in both neurodegenerative and alcohol-related disorders.